Myocardial tissue deformation is reduced in subjects with coronary microvascular dysfunction but not rescued by treatment with ranolazine.

ABSTRACT:

Background

Patients with coronary microvascular dysfunction (CMD) often have diastolic dysfunction, representing an important therapeutic target. Ranolazine-a late sodium current inhibitor-improves diastolic function in animal models and subjects with obstructive coronary artery disease (CAD).

Hypothesis

We hypothesized that ranolazine would beneficially alter diastolic function in CMD.

Methods

To test this hypothesis, we performed retrospective tissue tracking analysis to evaluate systolic/diastolic strain, using cardiac magnetic resonance imaging cine images acquired in a recently completed, randomized, double-blind, placebo-controlled, crossover trial of short-term ranolazine in subjects with CMD and from 43 healthy reference controls.

Results

Diastolic stra

SUBMITTER: Nelson MD 

PROVIDER: S-EPMC5436931 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature